Antitumor efficacy of recombinant interleukin 2-activated killer cells against endometrial cancers.
D000818:Animals; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D014594:Uterine Neoplasms / Q000628:therapy*
D007376:Interleukin-2